Shots:

• The companies filed for their Nesp biosimilar in Oct’2018 with its awaited launch in H2’19
• The original drug was developed in collaboration with US’ Amgen and Japan’s Kyowa Hakko while the patent expired in the US AND Korea in 2015 and 2024. The worldwide sales for Nesp is expected to be $3B 
• Nesp (darbepoetin alfa) is an erythropoietin drug and is a catalyst for red blood cell production involved in treating anemia from chronic renal failure or anticancer treatments

Click here to read full press release/ article | Ref: Korean Hearld | Image: Twitter